Related Experiment Video
Updated: May 12, 2026

06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer
David D Yang1,2,3, Aya Abdelnaser2, Alexander J Haas2,3
1Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.
Summary
Computational pathology reveals immune spatial clustering as a novel biomarker for prostate cancer (PCa) risk stratification. This interpretable approach identifies immune features linked to reduced distant metastasis risk in high-grade PCa.
Area of Science:
- Computational pathology
- Cancer research
- Immunology
Background:
- Computational pathology offers potential for prostate cancer (PCa) risk stratification.
- Existing methods often lack interpretability or focus solely on tumor morphology.
Purpose of the Study:
- To identify an interpretable computational pathology biomarker derived from the immune microenvironment for PCa.
- To assess the association between immune spatial clustering and distant metastasis in PCa patients.
Main Methods:
- Utilized two cohorts (n=490) with M0 PCa and whole-slide images (WSIs) for discovery and validation.
- Employed deep learning (CellViT) for immune cell identification and DBSCAN for spatial clustering.
- Performed immune cell deconvolution (CIBERSORTx) and immune receptor repertoire reconstruction (TRUST4).
Main Results:
- Increased immune spatial clustering was associated with a decreased risk of distant metastasis in high-grade (Gleason 8-10) PCa.
- This association was not observed in lower-grade (Gleason 6-7) PCa.
- High-cluster samples in Gleason 8-10 PCa were enriched for CD8+ T cells, Tregs, and clonal T cell populations.
Conclusions:
- Immune spatial clustering represents a novel, interpretable computational pathology biomarker for PCa.
- This biomarker provides insights into the distinct immune microenvironment of high-grade PCa.
- Findings support the utility of immune-based computational pathology for improved PCa risk assessment.

